WO2024003873 - SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
National phase entry is expected:
Publication Number
WO/2024/003873
Publication Date
04.01.2024
International Application No.
PCT/IB2023/056870
International Filing Date
30.06.2023
Title **
[English]
SINGLE VARIABLE DOMAIN ANTIBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
[French]
ANTICORPS À DOMAINE VARIABLE UNIQUE DIRIGÉS CONTRE LE FACTEUR ALPHA DE NÉCROSE TUMORALE
Applicants **
INTREXON ACTOBIOTICS NV D/B/A PRECIGEN ACTOBIO
Inventors
STEIDLER, Lothar
NEIRYNCK, Sabine A.S.
Priority Data
63/357,535
30.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2947 | |
| EPO | Filing, Examination, Granting | 12310 | |
| Japan | Filing, Examination, Granting | 2257 | |
| South Korea | Filing, Examination, Granting | 2162 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
25,316
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The current disclosure provides an antibody polypeptide comprising a single variable domain that specifically binds a human Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α). Also provided is a polynucleic acid encoding the described antibody polypeptide and a Gram- positive bacterium comprising the polynucleic acid. Further provided is a method of treating an inflammatory condition or a pathological condition by administering the Gram-positive bacterium.[French]
La présente divulgation concerne un polypeptide d'anticorps comprenant un domaine variable unique qui se lie de manière spécifique à un facteur de nécrose tumorale alpha humain (TNF-alpha ou TNF-α). L'invention concerne également un acide polynucléique codant pour le polypeptide d'anticorps décrit et une bactérie à Gram positif comprenant l'acide polynucléique. L'invention concerne en outre une méthode de traitement d'un état inflammatoire ou d'un état pathologique par administration de la bactérie à Gram positif.